Loading...
 
Translate Register Log In Login with facebookLogin and Register

Autism problems reduced by Vitamin D, Omega-3 – RCT Oct 2018

A randomised controlled trial of vitamin D and omega-3 long chain polyunsaturated fatty acids in the treatment of irritability and hyperactivity among children with Autism Spectrum Disorder

Hyperactivity

Image

Irritability

Image
The Journal of Steroid Biochemistry and Molecular Biology https://doi.org/10.1016/j.jsbmb.2018.10.017
Hajar Mazahery, Cathryn A. Conlon, Kathryn L.Beck, Owen Mugridge, Marlena C. Kruger, WelmaStonehouse, Carlos A. Camargo Jr., Barbara J. Meyer, BeatrixJones, Pamela R. von Hurst
Highlights

  • Irritability and hyperactivity were common in children with ASD.
  • Vitamin D and omega-3 reduced irritability symptoms in children with ASD.
  • Vitamin D reduced hyperactivity symptoms in children with ASD
VitaminDWiki

1 year trial
It is doubtful that the 2,000 IU dose would have resulted in a 40 ng level, the minimum found to be needed by many other studies
Interesting: Omega-3 boosted Vitamin D response
"Serum 25(OH)D concentration (nmol/L) increased by 27±14 in VID and by 36±17 in VIDOM groups.."


PDF is available free at Sci-Hub  10.1016/j.jsbmb.2018.10.017

Irritability and hyperactivity are common in children with Autism Spectrum Disorder (ASD). Because pharmacological treatments may have adverse effects, and despite limited evidence, caregivers/parents often use dietary supplements such as vitamin D and omega-3 fatty acids to address these behavioural symptoms. As a secondary objective of the VIDOMA (Vitamin D and Omega-3 in ASD) trial, we evaluated the efficacy of vitamin D, omega-3 long chain polyunsaturated fatty acid [omega-3 LCPUFA; docosahexaenoic acid (DHA)], or both on irritability and hyperactivity. New Zealand children with ASD (aged 2.5-8 years) participated in a 12-month randomized, double-blind, placebo-controlled trial of vitamin D (2000 IU/day, VID), omega-3 LCPUFA (722 mg/day DHA, OM), or both (2000 IU/day vitamin D + 722 mg/day DHA, VIDOM).
The primary outcomes were the Aberrant Behaviour Checklist (ABC) domains of irritability and hyperactivity. Biomarkers (serum 25-hydroxyvitamin D 25(OH)D and omega-3 index) and primary outcomes were measured at baseline and 12-months. Out of 111 children who completed baseline data collection, 66% completed the study (VID = 19, OM = 23, VIDOM = 15, placebo = 16).
After 12 months, children receiving OM (-5.0 ± 5.0, P = 0.001) and VID (-4.0±4.9, P = 0.01) had greater reduction in irritability than placebo (0.8±6.1).
Compared to placebo, children on VID also had greater reduction in hyperactivity (-5.2±6.3 vs. -0.8±5.6, P = 0.047). Serum 25(OH)D concentration (nmol/L, mean±SD) increased by 27±14 in VID and by 36±17 in VIDOM groups (P < 0.0001), and omega-3 index (%, median (25th, 75th percentiles)) by 4.4 (3.3, 5.9) in OM and by 4.0 (2.0, 6.0) in VIDOM groups (P < 0.0001), indicating a good compliance rate.
The results indicate that vitamin D and omega-3 LCPUFA reduced irritability symptoms in children with ASD. Vitamin D also reduced hyperactivity symptoms in these children.

Created by admin. Last Modification: Tuesday October 30, 2018 21:50:44 UTC by admin. (Version 5)

Attached files

ID Name Comment Uploaded Size Downloads
10758 Autism irritability.jpg admin 30 Oct, 2018 21:23 18.79 Kb 15
10757 Autism hyperactivity.jpg admin 30 Oct, 2018 21:23 19.54 Kb 13
See any problem with this page? Report it (FINALLY WORKS)